Clinical Cancer Research, Vol 1, Issue 7 769-773, Copyright © 1995 by American Association for Cancer Research

ARTICLES

p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma

I Shibagaki, H Tanaka, Y Shimada, T Wagata, M Ikenaga, M Imamura and K Ishizaki
Radiation Biology Center, First Department of Surgery, Faculty of Medicine, Kyoto University, Yoshida-konoecho, Sakyo-ku, Kyoto 606, Japan.

We examined the relationship between p53 mutation, murine double minute 2 (MDM2) gene amplification, and human papillomavirus (HPV) infection in 72 esophageal squamous cell carcinomas. We identified p53 mutations in 29 tumors (40.3%) by PCR-single-strand conformation polymorphism analysis and direct sequencing. Amplification of the MDM2 gene was detected by Southern blot hybridization in 13 (18.1%) of 72 tumor tissues and in 4 (33.3%) of 12 cultured esophageal squamous cell lines. All four cell lines with MDM2 amplifications showed overexpression of the MDM2 mRNA in Northern blotting. We observed HPV infection in 15 (20.8%) of 72 tumor tissues by specific PCR amplification and Southern blot hybridization. In most tumors, amplification of the MDM2 gene or infection of HPV was not associated with p53 mutations, except in four cases with p53 mutation and MDM2 amplification, and three cases with p53 mutation and HPV infection. Since p53 mutations, MDM2 overexpression, and HPV infection are all considered to abrogate the normal function of p53 protein, each of these genetic changes may be equally important in tumorigenesis. In addition, we found that patients with MDM2 amplification exhibited a significantly shorter survival period (P = 0.0053).

This article has been cited by other articles:

				Y. Shimada, M. Maeda, G. Watanabe, S. Yamasaki, I. Komoto, J. Kaganoi, T. Kan, Y. Hashimoto, I. Imoto, J. Inazawa, et al. Cell Culture in Esophageal Squamous Cell Carcinoma and the Association with Molecular Markers Clin. Cancer Res., January 1, 2003; 9(1): 243 - 249. [Abstract] [Full Text] [PDF]

				K J Syrjanen HPV infections and oesophageal cancer J. Clin. Pathol., October 1, 2002; 55(10): 721 - 728. [Abstract] [Full Text] [PDF]

				S.-I. Tsurusako, H. Tanaka, Y. Hayashi, I. Tohnai, M. Ueda, and K. Ishizaki Low Incidence of p53 Mutations in Well-differentiated Tongue Squamous Cell Carcinoma in Japan Jpn. J. Clin. Oncol., September 1, 2002; 32(9): 327 - 331. [Abstract] [Full Text] [PDF]

				X. Zhou, X. W. Wang, L. Xu, K. Hagiwara, M. Nagashima, R. Wolkowicz, I. Zurer, V. Rotter, and C. C. Harris COOH-Terminal Domain of p53 Modulates p53-mediated Transcriptional Transactivation, Cell Growth, and Apoptosis Cancer Res., February 1, 1999; 59(4): 843 - 848. [Abstract] [Full Text] [PDF]

				P. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, and N. P. Pavletich Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain Science, November 8, 1996; 274(5289): 948 - 953. [Abstract] [Full Text]